Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across multiple patient populationsPreliminary evidence of more robust anti-tumor activity and durable responses in GEP-NET patients whose target lesions all express SSTR2+ supports focusing on this populationBamzireotide continues to be well-tolerated Targeting End-of-Phase 2 meeting in 1Q 2027